We found that the patients with BC were characterised by the lower (p < 0.01) methylation level of the SOD2 promoter region (Fig. 5A) and higher NOS2 promoter methylation (p < 0.001) compared to the controls (Fig. 5B). This evidence concerns the gene NOS2 and breast cancer.